Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?

Current hematology reports

Volumn 4, Issue 3, 2005, Pages 182-185

  Sekeres, Mikkael A ^a   List, Alan ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DRUG DERIVATIVE; IMMUNOLOGIC FACTOR; LENALIDOMIDE; THALIDOMIDE;

AGED; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; REVIEW; SECRETION; TREATMENT OUTCOME;

AGED; CLINICAL TRIALS; CLINICAL TRIALS, PHASE II; CYTOKINES; FEMALE; HEMATOLOGIC DISEASES; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MULTICENTER STUDIES; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 23844431694     PISSN: None     EISSN: 15410714     Source Type: Journal    
DOI: None     Document Type: Review

References (21)